81 related articles for article (PubMed ID: 38571955)
1. Case report: Is severe toxicity the price to pay for high sensitivity to checkpoint inhibitors immunotherapy in desmoplastic melanoma?
Squicciarini T; Villani R; Apollonio B; Fucci L; Zambetti M; Rossini M; Pinto R; Tommasi S; De Roma I; Strippoli S; Guida M
Front Immunol; 2024; 15():1369531. PubMed ID: 38799429
[TBL] [Abstract][Full Text] [Related]
2. Autoimmune Encephalitis following Checkpoint Inhibitor Therapy in a Patient with Metastatic Melanoma in Complete Remission.
Civardi G; Medioli A; Braghieri C; Ambroggi M; Immovilli P; Orsucci S; Contini P; Aronica G; Cavanna L
Medicina (Kaunas); 2024 Apr; 60(5):. PubMed ID: 38792910
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy Rechallenge After Checkpoint Inhibitor Induced Hemophagocytic Lymphohistiocytosis: A Case Report and Literature Review.
Geusens D; Dierickx D; Carton S; Van Cutsem E; Dekervel J
Clin Colorectal Cancer; 2024 Jun; 23(2):194-197. PubMed ID: 38519390
[No Abstract] [Full Text] [Related]
4. Case report: Fatal overwhelming post-splenectomy infection in a patient with metastatic angiosarcoma treated with immunotherapy.
Torrado C; Baysal MA; Chakraborty A; Norris BL; Khawaja F; Tsimberidou AM
Front Immunol; 2024; 15():1366271. PubMed ID: 38779675
[TBL] [Abstract][Full Text] [Related]
5. Severe autoimmune hemolytic anemia following immunotherapy with checkpoint inhibitors in two patients with metastatic melanoma: a case report.
Fetter T; Fietz S; Bertlich M; Braegelmann C; de Vos-Hillebrand L; Wenzel J; Heine A; Landsberg J; Jansen P
Front Immunol; 2024; 15():1342845. PubMed ID: 38571955
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy-associated autoimmune hemolytic anemia.
Khan U; Ali F; Khurram MS; Zaka A; Hadid T
J Immunother Cancer; 2017; 5():15. PubMed ID: 28239468
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy-associated Autoimmune Hemolytic Anemia.
Hwang SR; Saliba AN; Wolanskyj-Spinner AP
Hematol Oncol Clin North Am; 2022 Apr; 36(2):365-380. PubMed ID: 35339260
[TBL] [Abstract][Full Text] [Related]
8. Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma.
Reddy SB; Possick JD; Kluger HM; Galan A; Han D
J Immunother; 2017 Oct; 40(8):307-311. PubMed ID: 28737620
[TBL] [Abstract][Full Text] [Related]
9. Auto-immune hemolytic anemia and hemophagocytic lymphohistiocytosis as immune-related adverse event in patients with metastatic melanoma and concurrent chronic lymphocytic leukemia: a case series and literature review.
Dirven I; Vander Mijnsbrugge AS; Mignon S; Tijtgat J; Kint N; Neyns B
Melanoma Res; 2023 Aug; 33(4):338-344. PubMed ID: 37114670
[TBL] [Abstract][Full Text] [Related]
10. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
11. Cost Savings and Increased Access With Ultra-Low-Dose Immunotherapy.
Mitchell AP; Goldstein DA
J Clin Oncol; 2023 Jan; 41(2):170-172. PubMed ID: 36265102
[No Abstract] [Full Text] [Related]
12. Timeline of Adverse Events during Immune Checkpoint Inhibitors for Advanced Melanoma and Their Impacts on Survival.
Villa-Crespo L; Podlipnik S; Anglada N; Izquierdo C; Giavedoni P; Iglesias P; Dominguez M; Aya F; Arance A; Malvehy J; Puig S; Carrera C
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267545
[TBL] [Abstract][Full Text] [Related]
13. Immune-checkpoint inhibitors: long-term implications of toxicity.
Johnson DB; Nebhan CA; Moslehi JJ; Balko JM
Nat Rev Clin Oncol; 2022 Apr; 19(4):254-267. PubMed ID: 35082367
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]